DUBLIN, June 10, 2016 /PRNewswire/-- Allergan plc
(NYSE: AGN), a leading global pharmaceutical company today
announced that new data presented at the American Headache Society
(AHS) annual scientific meeting reveals differences between the way
men and women react to migraines, suggesting underlying disparities
in headache characteristics and progression.i The
Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
longitudinally explored the causes and burden of Chronic Migraine
and Episodic Migraine, both part of the spectrum of migraine
disorders but distinct clinical entities. Chronic Migraine is a
neurological condition characterized by 15 or more headache days
per month, with headaches lasting four hours a day or longer, and
at least eight of those headache days being associated with
migraine, while Episodic Migraine is defined as less than 15
headache days per month.ii
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Migraine is one of the most common neurologic disorders in both
men and women, but its misperception as a "women's disease" may
contribute to migraine stigma in men.i The
web-based-study of 16,789 men and women with migraine assessed
differences in sociodemographics, headache symptomology,
disability, diagnosis, and treatment.i
"Despite gender differences in attack features, these conditions
are disabling in men. Chronic Migraine, in particular, has been
found to impact daily life inside and outside the home," explained
Dr. Richard B. Lipton, an Edwin S.
Lowe Professor and Vice Chair of Neurology, Professor of
Epidemiology and Population Health and Professor of Psychiatry and
Behavioral Sciences at the Albert Einstein College of
Medicine.iii "Men need to know that there are treatments
available and it's okay to ask for help."
Data indicated differences in the way men and women receive
diagnoses, interact with healthcare providers and manage the
conditions.
According to Dr. Lipton, "As we work to better understand
whether men have a different migraine pathophysiology than women,
it's important to encourage everyone – men and women – who is
experiencing symptoms to seek an accurate diagnosis."
Funding for the Chronic Migraine Epidemiology and Outcomes
(CaMEO) study was provided by Allergan plc.
"Allergan is dedicated to advancing research to help the
estimated 36 million Americans who are living with the debilitating
effects of migraine,[iv]" said David
Nicholson, Chief R&D Officer at Allergan. "The more
information patients have, the better equipped they will be to make
critical decisions about their own health, including when to seek
help and what treatment options are available."
For more information about Chronic Migraine, including a
screening tool, visit MyChronicMigraine.com.
About Allergan
Allergan plc (NYSE: AGN), headquartered
in Dublin, Ireland, is a unique,
global pharmaceutical company and a leader in a new industry model
– Growth Pharma. Allergan is focused on developing, manufacturing
and commercializing innovative branded pharmaceuticals,
high-quality generic and over-the-counter medicines and biologic
products for patients around the world.
Allergan markets a portfolio of best-in-class products that
provide valuable treatments for the central nervous system, eye
care, medical aesthetics, gastroenterology, women's health,
urology, cardiovascular and anti-infective therapeutic categories,
and operates the world's third-largest global generics business,
providing patients around the globe with increased access to
affordable, high-quality medicines. Allergan is an industry leader
in research and development, with one of the broadest development
pipelines in the pharmaceutical industry and a leading position in
the submission of generic product applications globally.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives.
For more information, visit Allergan's website at
www.allergan.com.
Forward-Looking Statement
Statements contained in this
press release that refer to future events or other non-historical
facts are forward-looking statements that reflect Allergan's
current perspective of existing trends and information as of the
date of this release. Except as expressly required by law, Allergan
disclaims any intent or obligation to update these forward-looking
statements. Actual results may differ materially from Allergan's
current expectations depending upon a number of factors affecting
Allergan's business. These factors include, among others, the
difficulty of predicting the timing or outcome of FDA approvals or
actions, if any; the impact of competitive products and pricing;
market acceptance of and continued demand for Allergan's products;
difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Annual Report on Form 10-K for the year ended
December 31, 2015 and Quarterly
Report on Form 10-Q for the quarter ended March 31, 2016 (certain of such periodic public
filings having been filed under the "Actavis plc" name). Except as
expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
For more information, visit Allergan's website at
www.allergan.com.
iScher I. Ann, PhD, et
al. Epidemiology of Migraine in Men: Results from the Chronic
Migraine Epidemiology and Outcomes (CaMEO) Study.
iiHeadache Classification Subcommittee of the
International Headache Society. The International Classification of
Headache Disorders: 3rd edition. Cephalalgia.
2013;33(9):629–808.
iiiKatsarava, Zaza, et al. "Defining the Differences
Between Episodic Migraine and Chronic Migraine." Current Pain
and Headache Reports.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258393/ (Nov. 15, 2011).
ivAmerican Migraine Foundation. "About Migraine."
http://www.americanmigrainefoundation.org/about-migraine/
(May 16, 2016)
CONTACTS:
Media:
Mark Marmur
(973) 906-1526
Lisa Kim
(714) 246-3843
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/study-reveals-gender-differences-in-migraine-treatment-300282890.html
SOURCE Allergan plc